Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AZ obtains exclusive access to select any cardiometabolic mRNA target plus selected oncology targets over five years, with rights to up to 40 development…
AstraZeneca and Moderna announced a multi-year collaboration valued at over $420M for mRNA therapeutics in cardiometabolic disease and cancer — described as…
AstraZeneca's decision to add another $140M equity investment in Moderna in 2016 deepens what began as a 2013 cardiometabolic and oncology mRNA deal,…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca paid $240M upfront + up to $180M technical milestones (total $420M) for 5-year exclusive option on mRNA targets in cardiometabolic plus selected oncology; up to 40 candidate selections plus dev/commercial milestones and royalties.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Moderna Therapeutics (this deal) | 2013 | $420M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2013 deals · AstraZeneca PLC deals · Cardiovascular deals